A Belfast health tech company which helps tackle diabetes, obesity and insomnia has appointed one of the world’s most respected medical device experts.
Neurovalens has made Tina Lai Liedtky, President of the Clinical Diagnostics Division at Massachusetts-headquartered scientific services giant Thermo Fisher Scientific, as a non-executive director.
The company, which creates non-invasive neurostimulation products used to solve some of the world's greatest health challenges, said Ms Liedtky will help it secure medical device approvals and commercialize its technology in both the metabolic and neurological area.
“I am delighted to welcome Tina to our board of directors at this very important time in Neurovalens' growth,” Dr Jason McKeown, Chief Executive of Neurovalens, said. “Tina's inspiring knowledge of the medical device sector and her passion for innovation will be key assets.”
As President of Clinical Diagnostics at Thermo Fisher Scientific, Tina currently oversees a $1 billion division with over 2,300 employees. She has previously held commercial leadership roles for Abbott Diabetes Care, commercializing a breakthrough continuous glucose monitoring device for diabetes management, and Abbott Rapid Diagnostics, managing their Cardiometabolic business with the world’s leading point-of-care HbA1c platform.
She has also worked at Boston Scientific and Covidien (Medtronic) where her focus was on opportunities to expand indications for the implanted neuromodulation technology in the areas of headache and Parkinson's disease, and in the area of neurovascular intervention.
“This is an exciting time for Neurovalens as the company expands its platform technology to address Type 2 Diabetes and PTSD,” Tina Lai Liedtky said. “The ambitious target of achieving multiple FDA approvals will allow them to tackle some of the most challenging healthcare issues across the world.
“I look forward to working closely with Neurovalens' leadership team as they press forward with their commercial strategy.
Neurovalens, which is dual headquartered in both Belfast and San Diego, last year raised £5.2m in funding from UK and Irish investors, which has been used to expand existing clinical trials, fund new trials and develop the application of its technology to the treatment of a wider range of conditions.
